- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Joe O'Sullivan Explains Education of Patients and Physicians on Molecular Therapies
Physicians using molecular therapies need to be educated on where the therapies are best used during treatment, and patients need to understand that the radiation is safe for those around them, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Physicians using molecular therapies need to be educated on where the therapies are best used during treatment, and patients need to understand that the radiation is safe for those around them, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
When using molecular therapies, is there a need for education among both patients and providers?
I think there is a need for education among the providers, first of all, in understanding where therapies like this should be best used. And they need to be used, if they’re used as a single agent, they need to be used at a time when the prostate cancer has not yet spread to visceral metastases—for example, liver or lung. So it needs to be bone only. And they also need to understand that a positive bone scan, a technetium bone scan, is required in order to say that, “this particular patient would benefit from this approach.” Because, if it’s not seen on a technetium scan, it’s unlikely that much radium will get into the bones.
Now, with regards to patient education, mostly it’s explaining to them what’s involved, making sure that they know there really is no radiation risk to anyone around them, because some patients worry about a radioactive treatment and that it might affect the people around them. Part of the education is reassuring them that this particular type of radiation is safe with other people.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
